Literature DB >> 30207578

Evaluation of Impact of Interferon-Induced Helicase C Domain-Containing Protein 1 Gene in Egyptian Systemic Lupus Erythematosus Patients and its Relationship With Vascular Manifestations of the Disease.

Sahar Nassef1, Mervat Essam2, Dina Abdelfattah3, Doaa Elsehemy2, Sahar Abouelezz2.   

Abstract

OBJECTIVES: This study aims to investigate the impact of interferon-induced helicase C domain-containing protein 1 (IFIH1) gene single nucleotide polymorphism on interferon pathway signaling in systemic lupus erythematosus (SLE) patients specifically with vascular affection. PATIENTS AND METHODS: The cross-sectional study included 30 consecutive SLE patients (2 males, 28 females; mean age 28±3.4 years; range 16 to 40 years) diagnosed according to the American College of Rheumatology revised criteria and 10 healthy age- and sex-matched controls (2 males, 8 females; mean age 27±2.5 years; range 22 to 23 years). SLE patients and controls were compared in terms of quantitative reverse transcriptase polymerase chain reaction gene expression of IFIH1 gene, von Willebrand factor, carotid intima-media thickness, and ankle brachial index.
RESULTS: Interferon-induced helicase C domain-containing protein 1 gene expression was significantly higher in SLE patients than controls (1.7±0.6 and 0.5±0.2, respectively) (p<0.0001). IFIH1 gene expression was highly related to vascular complication with a cutoff point at 1.74 and it positively correlated with other endothelial dysfunction markers.
CONCLUSION: Interferon-induced helicase C domain-containing protein 1 gene (single nucleotide polymorphism 1990670) is associated with SLE in Egyptian patients. Expression of IFIH1 gene is related to disease activity and may serve as a novel predictor of vascular affection in SLE.

Entities:  

Keywords:  Interferon-induced helicase C domain-containing protein 1 gene; vascular; von Willebrand factor

Year:  2018        PMID: 30207578      PMCID: PMC6117131          DOI: 10.5606/ArchRheumatol.2018.6476

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  21 in total

1.  Digital ulcers as an initial manifestation of systemic lupus erythematosus.

Authors:  Edoardo Rosato; Ilenia Molinaro; Simonetta Pisarri; Felice Salsano
Journal:  Intern Med       Date:  2011-04-01       Impact factor: 1.271

Review 2.  Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis.

Authors:  Pascal N Tyrrell; Joseph Beyene; Brian M Feldman; Brian W McCrindle; Earl D Silverman; Timothy J Bradley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-11       Impact factor: 8.311

3.  Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus.

Authors:  Rodolfo V Curiel; Rajkumari Bhagati; Lakshmi Basavaraju; Delona Norton; James Katz; Elizabeth Haile; Arthur Weinstein
Journal:  HSS J       Date:  2008-07-01

4.  Contribution of IKBKE and IFIH1 gene variants to SLE susceptibility.

Authors:  C Wang; A Ahlford; N Laxman; G Nordmark; M-L Eloranta; I Gunnarsson; E Svenungsson; L Padyukov; G Sturfelt; A Jönsen; A A Bengtsson; L Truedsson; S Rantapää-Dahlqvist; C Sjöwall; J K Sandling; L Rönnblom; A-C Syvänen
Journal:  Genes Immun       Date:  2013-03-28       Impact factor: 2.676

5.  Small artery elasticity is decreased in patients with systemic lupus erythematosus without increased intima media thickness.

Authors:  Hans L A Nienhuis; Karina de Leeuw; Johan Bijzet; Jasper J van Doormaal; Arie M van Roon; Andries J Smit; Reindert Graaff; Cees G M Kallenberg; Marc Bijl
Journal:  Arthritis Res Ther       Date:  2010-09-28       Impact factor: 5.156

6.  Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.

Authors:  M Petri; S Singh; H Tesfasyone; R Dedrick; K Fry; Pg Lal; G Williams; Jw Bauer; Pk Gregersen; Tw Behrens; Ec Baechler
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

Review 7.  The genetics of lupus: a functional perspective.

Authors:  Sandra G Guerra; Timothy J Vyse; Deborah S Cunninghame Graham
Journal:  Arthritis Res Ther       Date:  2012-05-29       Impact factor: 5.156

Review 8.  The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Arthritis Res Ther       Date:  2011-02-28       Impact factor: 5.156

9.  Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production.

Authors:  Julio E Molineros; Amit K Maiti; Celi Sun; Loren L Looger; Shizhong Han; Xana Kim-Howard; Stuart Glenn; Adam Adler; Jennifer A Kelly; Timothy B Niewold; Gary S Gilkeson; Elizabeth E Brown; Graciela S Alarcón; Jeffrey C Edberg; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Luis M Vilá; Barry I Freedman; Betty P Tsao; Lindsey A Criswell; Chaim O Jacob; Jason H Moore; Timothy J Vyse; Carl L Langefeld; Joel M Guthridge; Patrick M Gaffney; Kathy L Moser; R Hal Scofield; Marta E Alarcón-Riquelme; Scott M Williams; Joan T Merrill; Judith A James; Kenneth M Kaufman; Robert P Kimberly; John B Harley; Swapan K Nath
Journal:  PLoS Genet       Date:  2013-02-18       Impact factor: 5.917

10.  Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.

Authors:  Johanna Gustafsson; Iva Gunnarsson; Ola Börjesson; Susanne Pettersson; Sonia Möller; Guo-Zhong Fei; Kerstin Elvin; Julia F Simard; Lars-Olof Hansson; Ingrid E Lundberg; Anders Larsson; Elisabet Svenungsson
Journal:  Arthritis Res Ther       Date:  2009-12-10       Impact factor: 5.156

View more
  1 in total

1.  Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Laura Atehortúa; Mauricio Rojas; Gloria Vásquez; Carlos H Muñoz-Vahos; Adriana Vanegas-García; Rafael Andrés Posada-Duque; Diana Castaño
Journal:  Arthritis Res Ther       Date:  2019-01-23       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.